case_images: PMC10791132_01
case_images: Kidney function and BCR-ABL results while receiving asciminib.
case_images: cro-2024-0017-0001-535958_F01.jpg
case_images: PMC10791132_01_cro-2024-0017-0001-535958_F01.jpg
case_images: F1
case_images: TKIs like nilotinib, dasatinib, and ponatinib might worsen these preexisting conditions, as an alternative, asciminib at a dose of 40 mg twice daily (BID) was offered. The patient was counseled that there is no evidence that shifting to asciminib will protect his kidney since it is a new medicine and there is no study to prove or disprove; however, he agreed to start asciminib with close monitoring of kidney function which remains stable with maintaining deep molecular response (Fig. 1).